Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$7.29
+0.8%
$6.53
$4.64
$61.90
$89.21M3.19203,183 shs43,139 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.24
-3.4%
$1.04
$0.77
$3.12
$102.19M0.98362,033 shs83,256 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$6.33
+0.4%
$7.47
$5.35
$47.45
$23.29M-1.78159,268 shs10,671 shs
TVRD
Cara Therapeutics
$29.97
-2.9%
$0.00
$8.13
$34.31
$93.36M0.2120,551 shs15,674 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-1.77%-2.43%-3.60%-1.36%-83.06%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+10.34%+20.75%+18.52%+8.47%-45.42%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
+1.94%0.00%-19.54%-38.72%-84.86%
TVRD
Cara Therapeutics
-7.58%+3,085,999,900.00%+3,085,999,900.00%+3,085,999,900.00%+3,085,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4.1071 of 5 stars
4.60.00.04.73.21.70.0
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.4499 of 5 stars
3.74.00.00.02.20.00.6
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.7414 of 5 stars
3.33.00.00.02.00.00.6
TVRD
Cara Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.10
Buy$50.88597.87% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.40
Buy$8.67601.19% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2.50
Moderate Buy$30.00374.31% Upside
TVRD
Cara Therapeutics
3.00
Buy$65.00116.88% Upside

Current Analyst Ratings Breakdown

Latest TPST, CRDL, TVRD, and CRBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
TVRD
Cara Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $40.00
4/16/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$16.00 ➝ $16.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.00
4/7/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/28/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.00
3/28/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$611.00 ➝ $208.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A($1.56) per shareN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.39 per shareN/A
TVRD
Cara Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$44.60M-$4.22N/AN/AN/AN/A-42.28%-32.92%8/5/2025 (Estimated)
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$29.49M-$17.98N/AN/AN/AN/A-187.44%-82.61%8/14/2025 (Estimated)
TVRD
Cara Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A

Latest TPST, CRDL, TVRD, and CRBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.71-$3.16+$0.55-$3.16N/AN/A
5/6/2025Q1 2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.26-$1.39-$0.13-$1.39N/AN/A
3/31/2025Q4 2024
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.08-$0.07+$0.01-$0.07N/AN/A
3/27/2025Q4 2024
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.12-$4.03-$0.91-$0.31N/A$0.49 million
3/11/2025Q4 2024
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.02-$0.78+$0.24-$0.78N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
TVRD
Cara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
13.84
13.84
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
2.49
2.49
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
1.69
1.69
TVRD
Cara Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%
TVRD
Cara Therapeutics
44.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4012.24 million11.69 millionOptionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2082.61 million78.27 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
203.68 million41.59 millionOptionable
TVRD
Cara Therapeutics
803.12 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$7.29 +0.06 (+0.83%)
As of 11:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.24 -0.04 (-3.44%)
As of 11:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$6.32 +0.03 (+0.40%)
As of 11:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Cara Therapeutics NASDAQ:TVRD

$29.97 -0.89 (-2.88%)
As of 11:03 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.